Canadians spend $20 billion on Pharmaceuticals every year, making it the second-largest cost in the health-care sector. Helping practitioners access the most current information to make therapeutic decisions for patients can save money — and even lives. Vioxx, a COX-2 inhibitor for arthritis, was pulled off the market last year after research showed it could increase the risk of heart attacks and strokes. Celebrex, another COX-2 inhibitor, made the news when health officials announced they had received 100 reports of adverse reactions to the drag, including 14 deaths.
展开▼
